Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
Alberto Juan, María del Mar Noblejas‐López, María Arenas-Moreira, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 22

Showing 22 citing articles:

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer
Kailee A. Rutherford, Kirk J. McManus
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 454-463
Open Access | Times Cited: 17
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Jin Li, Xinxin Chen, Aiping Lü, et al.
The Innovation (2023) Vol. 4, Iss. 3, pp. 100413-100413
Open Access | Times Cited: 35
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Selective Protein of Interest Degradation through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach
Chunli Song, Zijun Jiao, Zhanfeng Hou, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 40, pp. 21860-21870
Closed Access | Times Cited: 23
Proteomic approaches advancing targeted protein degradation
Gajanan Sathe, Gopal P. Sapkota
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 786-801
Open Access | Times Cited: 21
Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
Toshihiko Tashima
Antibodies (2023) Vol. 12, Iss. 3, pp. 43-43
Open Access | Times Cited: 20
Inhibitors to degraders: Changing paradigm in drug discovery
V. Haridas, Souvik Dutta, Akshay Munjal, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109574-109574
Open Access | Times Cited: 7
Prodrug Approach as a Strategy to Enhance Drug Permeability
Mariana Moraes Dionysio de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 297-297
Open Access
TACkling Cancer by Targeting Selective Protein Degradation
María del Mar Noblejas‐López, David Tébar-García, Raquel López-Rosa, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2442-2442
Open Access | Times Cited: 11
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Yue Song, Qing‐Qing Dong, Yi-Ke Ni, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 5739-5761
Open Access | Times Cited: 4
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15440-15440
Open Access | Times Cited: 15
Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo
Qingna Jiang, Yan Hu, Quanyu Liu, et al.
Journal of drug targeting (2023) Vol. 31, Iss. 4, pp. 411-420
Closed Access | Times Cited: 7
Recent advances in dual PROTACs degrader strategies for disease treatment
Jianyu Liu, Yanzhuo Liu, Jiao Tang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116901-116901
Closed Access | Times Cited: 2
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 1
Evaluation of cereblon expression in gastrointestinal tract tumors
Mustafa Değirmenci
Research Square (Research Square) (2024)
Open Access
Unlocking Cellular Control: The Promise of PROTACs in Disease Intervention
Aishani Kumar, Thendral Yalini, Sunil Kumar C
Science Reviews Biology (2024) Vol. 3, Iss. 2, pp. 1-12
Open Access
Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation
Cristina Díaz‐Tejeiro, María Arenas-Moreira, Adrián Sanvicente, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117165-117165
Open Access
Delivery Systems: Miniaturised PROTAC, Nano PROTAC, and Aptamer-Based RNA PROTAC
Manish P. Patel, Hard K. Kalyani, Kashyap M. Patel, et al.
(2024), pp. 367-385
Closed Access
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Akash Vikal, Rashmi Maurya, Brij Bihari Patel, et al.
Drug Delivery and Translational Research (2024)
Closed Access
Targeted Protein Degraders- The Druggability Perspective
Satinder Singh, Pratima Srivastava
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 3, pp. 539-554
Closed Access
Page 1

Scroll to top